2023 World Conference on Lung Cancer (Posters)-EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients?

EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients? - PDF(Abstract)

Back to course

Pdf Summary

The study aimed to evaluate the impact of a new haemostatic agent called Microporous Polysaccharide Hemospheres (ARISTA) on the short-term outcomes of surgically treated non-small cell lung cancer patients. The researchers retrospectively reviewed a database of early-stage lung cancer patients who underwent surgery in two European centers from October 2020 to December 2022. The cohort was divided into five groups based on the use of haemostatic agents. They analyzed the patients' outcomes using univariate analysis and linear regression models adjusted for various factors. <br /><br />A total of 482 patients were included in the analysis, and ARISTA was used intraoperatively in 226 cases. The use of ARISTA was associated with significant reductions in surgical time, hospitalization duration, chest tube duration, and the total amount of fluid drained compared to other haemostatic agents. Linear regression analysis confirmed the superior results of ARISTA in terms of these outcomes. No bleeding, blood transfusion, 30-day mortality, or redo-surgeries were observed in the ARISTA group. <br /><br />The findings suggest that Microporous Polysaccharide Hemospheres is a safe and effective haemostatic device. Its use in lung cancer surgery has positive effects on short-term postoperative outcomes. These results are important because intraoperative and postoperative blood loss can be life-threatening complications in lung cancer surgery, especially minimally invasive procedures. The use of ARISTA could potentially improve patient outcomes and reduce the need for blood transfusions.

Asset Subtitle

Sara Ricciardi

Meta Tag

Speaker Sara Ricciardi

Topic Early-Stage NSCLC: Best Practice

Keywords

haemostatic agent

Microporous Polysaccharide Hemospheres

ARISTA

short-term outcomes

surgically treated

non-small cell lung cancer

retrospective review

early-stage lung cancer

univariate analysis

linear regression models